X14ed6d5a.d8f1.41aa.93e1.fba99596f5fd
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.300
- ALLOGRAFT_REJECTION+0.270
- INTERFERON_ALPHA_RESPONSE+0.240
- IL6_JAK_STAT3_SIGNALING+0.190
- INTERFERON_GAMMA_RESPONSE+0.170
- KRAS_SIGNALING_DN+0.160
- HEME_METABOLISM+0.100
- IL2_STAT5_SIGNALING+0.100
- APOPTOSIS+0.080
- BILE_ACID_METABOLISM+0.050
Top 10 suppressed
- G2M_CHECKPOINT-0.520
- MTORC1_SIGNALING-0.500
- E2F_TARGETS-0.490
- ANGIOGENESIS-0.430
- MITOTIC_SPINDLE-0.410
- GLYCOLYSIS-0.370
- MYC_TARGETS_V2-0.360
- MYC_TARGETS_V1-0.340
- PROTEIN_SECRETION-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.846 |
| 2 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.843 |
| 3 | ULC0542T_S55 | — | cohortMD2 | 0.840 |
| 4 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.836 |
| 5 | SRR13780258 | — | cohortMD2 | 0.834 |
| 6 | TCGA-97-A4M0-01A-11R-A24X-07 | — | cohortA1 | 0.832 |
| 7 | 6b907244-c173-4e29-a163-24258a430477 | — | — | 0.830 |
| 8 | s0112296 | — | — | 0.820 |
| 9 | TCGA-CF-A47S-01A-11R-A23W-07 | — | — | 0.820 |
| 10 | SRR1313099 | — | A | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |